To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
-
UCSF Medical Center, San Francisco, California, United States, 94143
Stanford Medical Center, Stanford, California, United States, 94305
University of Colorado, Aurora, Colorado, United States, 80045
Northwestern University, Chicago, Illinois, United States, 60611
Tufts University, Boston, Massachusetts, United States, 02111
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115
University of Minnesota, Minneapolis, Minnesota, United States, 55455
Duke University, Durham, North Carolina, United States, 27708
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 71 Years
ALL
No
Sonoma Biotherapeutics, Inc.,
Dr. Mei-Lun Wang, MD, STUDY_DIRECTOR, Sonoma Biotherapeutics
2040-12